在使用HBcAb+捐赠者进行移植后,是否需要进行抗病毒预防? 一个系统的审查和元分析
Saifu Yin1, Xiaoting Chen2, Xingxing Li3
1Department of Urology/Institute of Urology, West China Hospital, Sichuan University, Chengdu City, Sichuan Province, China; Kidney Transplantation Center, West China Hospital, Sichuan University, Chengdu City, Sichuan Province, China.
使用乙型肝炎核心抗体阳性 (HBcAb+) 供体进行移植的肝炎乙型肝炎病毒 (HBV) 感染新发的风险非常低. 抗病毒预防仅适用于乙型肝炎表面抗体阴性和HBcAb阳性接受者.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 肝病学 肝病学是一种肝病学.
- 移植免疫学 移植免疫学
背景情况:
- 针对肝炎B核抗体阳性 (HBcAb+) 器官捐赠者的脏接受者,关于抗病毒预防的指导方针有所不同.
- 本研究评估了新的乙型肝炎病毒 (HBV) 感染发病率,风险因素和使用HBcAb+捐赠者的脏移植中的生存结果.
结论:
- 使用HBcAb+捐赠者的移植产生了可比的移植和患者存活率,HBV传播风险最小.
- 针对HBsAb-/HBcAb+接受者的抗病毒预防特别适用,以预防新的HBV感染.
更多相关视频
08:04Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
Published on: July 9, 2014
10:24Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System
Published on: October 5, 2015
相关概念视频
Retrovirus Life Cycles
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
